HEALTH TECHNOLOGY

Easterseals and the Abbott Fund Join Together to Advance Education and Health Equity

Easterseals | June 23, 2022

Easterseals

Easterseals announced today that it has received a grant of $750,000 from the Abbott Fund, the foundation of the global healthcare company Abbott, to pilot the Project on Education and Community Health Equity from now through 2025. The three-year project aims to address systemic barriers to high-quality education and healthcare experienced by children and families in underinvested communities.

Research shows that many young children, particularly children with disabilities and children of color, face significant gaps in access to crucial health and social services that can provide the targeted support they need to be prepared to succeed in school. One example: according to a study by the American Academy of Pediatrics, Black children with autism and other disabilities are diagnosed an average of more than three years after their parents expressed concerns about their development. This delay in diagnosis means these children miss out on age-appropriate care and the chance to improve their health and cognitive skills, often resulting in them entering kindergarten with knowledge and skill deficits that many are not able to overcome throughout their K-12 educational journey.

The Project on Education and Community Health Equity will create an integrated system that addresses the educational and healthcare needs of children to help them be kindergarten ready and reach their full potential. This includes work in three areas: expanding access to essential physical and mental health screenings and care for children; providing targeted social services to help families overcome gaps in basic needs, nutrition, transportation, and other social and economic barriers; and ensuring that early childhood administrators and educators have the right training to identify and address health and social challenges and provide culturally appropriate support for children. The project will be implemented at Easterseals Childhood Development Centers in Southern California, Atlanta and North Georgia, and the greater Washington, D.C., area.

"Addressing the healthcare needs of infants and toddlers as early as possible in their lives is one of the critical ways in which Easterseals serves young children and families across the country. The Project on Education and Community Health Equity will allow us to better address healthcare disparities experienced by young BIPOC children and their families in historically underserved and marginalized communities, and to better understand the connection between more equitable access to healthcare and kindergarten readiness. Centering communities of color in our efforts is a critical strategy to close the gap. Outcomes from the project promise to inform its future expansion to early childhood and early education programs throughout the Easterseals Network of 70 affiliates in communities nationwide."

 Erika L. Watson, National Director of Childhood Development, Education and Equity at Easterseals

"We're proud to support Easterseals' important work to help close equity gaps in education and community health," said Melissa Brotz, president of the Abbott Fund and vice president of Global Marketing and External Affairs at Abbott. "We're committed to advancing health equity and fighting racial health disparities, and our partnership with Easterseals will help reduce barriers to care for children, their families and their communities."

The Project on Education and Community Health Equity builds on results seen through another Easterseals program, the Black Child Fund. Launched in 2021 with support from the Abbott Fund and others, the Black Child Fund advanced early identification and interventions among Black children with autism and other disabilities to reduce health disparities often experienced in early childhood. The Abbott Fund investment launched pilots at Easterseals locations serving Chicagoland and Greater Rockford, DuPage and the Fox Valley Region (IL), and Kansas City and St. Louis (MO).

Through these pilot programs, an 87% increase in the number of Black families seeking services and support was realized, with more than 300 Black children screened for early diagnosis of autism and other disabilities in just one year. Of these children, 80% were five years old or younger, with 75% requiring and receiving additional services through Easterseals. An important outcome of these pilots has been the strengthening of relationships within Black communities across these Easterseals service areas to ensure more equitable and more culturally responsive services and supports to young children of color with disabilities and their families.

The Centers for Medicare and Medicaid Services (CMS) released data revealing that during the pandemic public health emergency, rates for primary and preventive services among children in Medicaid and the Children's Health Insurance Program (CHIP) declined substantially. This decline in care for millions of children from low-income families will potentially have a significant impact on long-term health outcomes for the nearly 40 million children in the U.S. who rely on Medicaid and CHIP, including three-quarters of children living in poverty and many with special healthcare needs including infants, toddlers, and young children with disabilities.

"Through the Project on Education and Community Health Equity, it is Easterseals' intention to address the disparities in healthcare among young children in low-investment communities and to understand the connection between health equity and early childhood educational attainment. We intend to center the experiences of children of color and their families, for whom inequities have only been exacerbated because of the pandemic," Watson concluded.

The Abbott Fund's partnership with Easterseals supports Abbott's 2030 Sustainability Plan, which aims to advance health access and equity through partnership. Abbott's ongoing commitment to address health equity challenges includes targeted programs to increase diversity in clinical trials, create opportunities in STEM for women and underrepresented groups, and empower communities to break down social and economic barriers to better health.

About Easterseals
Easterseals is leading the way to full equity, inclusion, and access through life-changing disability and community services. For more than 100 years, we have worked tirelessly with our partners to enhance quality of life and expand local access to healthcare, education, and employment opportunities.  And we won't rest until every one of us is valued, respected, and accepted. Through our national network of Affiliates, Easterseals provides essential services and on-the-ground supports to more than 1.5 million people each year – from early childhood programs for the critical first five years, to autism services, medical rehabilitation and employment programs, veterans' services, and more. Our public education, policy, and advocacy initiatives positively shape perceptions and address the urgent and evolving needs of the one in four Americans living with disabilities today. Together, we're empowering people with disabilities, families, and communities to be full and equal participants in society.  

About Abbott and the Abbott Fund
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 113,000 colleagues serve people in more than 160 countries.

Spotlight

Human resources executives are making significant investments in health benefits and health-related services for employees, but the Accolade Consumer Healthcare Experience Index survey indicates that they could get more for their healthcare investments by factoring how age and life circumstances influence how people use and experience their health benefits. These and other findings were drawn from a national survey conducted online by Harris Poll, on behalf of Accolade, an on-demand healthcare concierge for employers, health plans, and health systems.


Other News
HEALTH TECHNOLOGY

athenahealth Expands Mobile EHR Voice Capabilities for Healthcare Providers

athenahealth, Inc. | June 29, 2022

athenahealth, Inc., a leading provider of network-enabled software and services for medical groups and health systems nationwide, announced the release of athenaOne® Voice Assistant Powered by Nuance®, a mobile-embedded, voice-driven digital companion that streamlines information retrieval and enables hands-free completion of meaningful clinical tasks for healthcare providers using athenahealth’s electronic health records (EHR) solution. Leveraging the power of their voice and iOS-based mobile device, clinicians can spend less time on the computer and more time interacting with patients. Voice Assistant is a natural command-based, virtual assistant developed and built by athenahealth and powered by Nuance's Dragon Medical technology. Voice Assistant is available for use with the award-winning athenaOne mobile app and athenaOne® Dictation Powered by Nuance®, which allows clinicians to dictate patient documentation naturally and accurately. Together, athenahealth’s voice-enabled solutions help clinicians improve documentation accuracy, save time, and provide a better patient experience. According to a recent survey by athenahealth, 92% of physicians surveyed report one or more issues cause them to feel burned out on a regular basis with the leading cause of regular burnout being excessive documentation requirements. However, numerous clinicians using Voice Assistant have experienced significant documentation time savings, thus allowing them to reallocate their time to other high-priority tasks. “I started using Voice Assistant because I’m curious about tech and AI, and I wanted to see if it would help me be more productive. Because I can so easily document anywhere, anytime, I’ve found it to be very useful and convenient, and it helps me make better use of my time. I wouldn’t want to work without it now.” Dr. Terence M. Grogan, DO, FAAFP, Grogan Family Medicine Using simple, intuitive voice commands, clinicians using Voice Assistant can document exams, create draft orders, retrieve clinical information, and review their schedule to accelerate tasks and save valuable time. As an AI-backed technology, Voice Assistant will become even smarter and more efficient with widespread use, and athenahealth will continue to expand the number of available commands and introduce new use cases. “We are delighted to expand our provider mobile app capabilities with Voice Assistant as we continue to transform the provider and patient experience,” said Paul Brient, chief product officer for athenahealth. “Clinicians should be able to experience technology at work just like they do in their everyday lives, and Voice Assistant brings us one step closer to that.” Brient added that with provider burnout and patient expectations increasing simultaneously, athenahealth is focused on accelerating product innovation, using tools like AI to help solve some of healthcare's biggest challenges. “As our data show, administrative requirements are taking too much time and attention away from providers, and it’s the responsibility of all EHR companies to decrease that burden so providers can spend more face time with patients,” he said. About athenahealth, Inc. athenahealth creates innovative healthcare technology that connects clinicians, patients, payers, and partners in differentiated ways. Our electronic health records, revenue cycle management, and patient engagement tools allow anytime, anywhere access, driving better financial outcomes for our customers and enabling our provider customers to deliver better quality care. In everything we do, we’re inspired by our vision to create a thriving ecosystem that delivers accessible, high-quality, and sustainable healthcare for all.

Read More

HEALTH TECHNOLOGY

Health Care Software Provider GoMeyra Announces Partnership with Visit Healthcare

GoMeyra | July 20, 2022

GoMeyra, a cloud software company dedicated to providing innovative, real-time software for the health care industry, announces partnership with Visit Healthcare, a nationwide turnkey mobile medical provider. GoMeyra’s laboratory information management system (LIMS) will now power the health care company’s onsite lab diagnostic testing, immunizations and other medical solutions for enterprise-level clients. “Our need for a reliable technology partner has increased tremendously in the past few years, and the portals we have been using have limited flexibility, especially as we move into mobile medical services beyond COVID. GoMeyra has already bolstered our mobile capabilities with its versatile technology that has the ability to customize to our clients’ changing needs. Their team is quick to respond and the reporting process is simple. We also work with many of the same clients, so the transition to a new system has been easy. They are a great match for us” Visit Healthcare CEO, Olympia Bliss GoMeyra’s Laboratory Information Management Solution is a revolutionary, cloud-based software platform solution that empowers labs, health care facilities and medical practices to achieve unprecedented processing times for COVID-19 RT-PCR, rapid PCR, antigen, antibody and serology testing while automating procedures and managing samples faster and more accurately. New testing panels will be added in the very near future. “Visit Healthcare is growing fast, and like many growing companies, they need technology to be more agile and evolve with their business. Many companies, when they start out, don’t realize how important this flexibility is until they outgrow their current system. We offer medical practitioners a painless transition and peace of mind so they can focus on operations and not worry about their technology needs,” added GoMeyra Founder and Chief Executive Officer, Jaswant S. Tony. Visit Healthcare will also have access to GoVirtual Clinic, GoMeyra’s newly launched telehealth platform, which is fully integrated with GoMeyra LIMS. GoVirtual Clinic is a next-generation platform that includes a suite of solutions for medical professionals to conduct virtual patient appointments while comprehensively managing patient care and related electronic health records. The first phase of the platform features ways to seamlessly schedule and manage virtual testing appointments, order test kits, monitor online waiting rooms, conduct virtual appointments, and share test results with patients in real-time. For product demonstrations, contact info@GoMeyra.com or call (844) 203-3960. About GoMeyra GoMeyra is a trusted technology partner providing innovative, real-time software solutions that simplifies processes and delivers unparalleled customer service for the health care industry. GoMeyra’s premiere product, GoMeyra LIMS, is an automated, customizable laboratory information management system that improves workflow efficiencies, enabling laboratories, medical providers, employers and enterprise organizations to process lab tests and deliver patient results with unprecedented speed. GoMeyra Network, a unique built-in feature, allows independent labs across the country to collaborate and compete with larger diagnostic providers. About Visit Healthcare Visit Healthcare, a nationwide turnkey mobile medical provider, works with states, counties, government agencies, schools, and private industry on rapid response healthcare solutions. With a background in emergency response, Visit Healthcare has a proven ability to mobilize health care workers across the country in a very short period of time and currently operates testing and/or vaccination services in more than 26 states. With healthcare professionals and numerous CLIA-certified high-complexity laboratories at the ready, Visit Healthcare plays an active role in additional health care services including flu​ clinics, telehealth, and molecular testing beyond COVID-19.

Read More

HEALTH TECHNOLOGY

Vitestro unveils autonomous blood drawing device, combining artificial intelligence, ultrasound imaging and robotics

Vitestro | May 31, 2022

Vitestro, a Dutch medical robotics company, unveiled the world's most advanced autonomous blood drawing device at the annual meeting of the Netherlands Society for Clinical Chemistry and Laboratory Medicine in Rotterdam. Vitestro's device combines AI-based, ultrasound-guided 3D reconstruction with robotic needle insertion, ensuring accurate and secure blood collection. The venipuncture technology is adaptable to patients of 16 years of age onwards, comorbidities, and puncture difficulty. From 2023, Vitestro will initiate pivotal clinical studies for regulatory approval in Europe. EU-market introduction is anticipated in 2024. Healthcare shortages spark revolutionary developments Within healthcare, the clinical laboratory is the driving force. Accuracy and timeliness of laboratory tests are critically important, as they shape approximately 70% of all medical decisions made by physicians. It is unsurprising that blood collection is the most common invasive medical procedure, performed billions of times per year globally. Blood collection holds a pivotal role in clinical diagnostics yet is also burdened by the scarcity of skilled workers. By automating this labor-intensive procedure, we can transform the quality of care and create a sustainable healthcare system. Proprietary laboratory automation technology standardizes handling of the blood sample while the blood is collected. The device allows almost complete automation of the pre-analytical phase. This has the potential to reduce high blood test error rates, mainly caused by manual variability. In clinical studies, Vitestro already performed 1,500 automated blood draws in more than 1,000 patients with its prototype. Toon Overbeeke, Vitestro's Co-Founder and Chief Executive Officer said: "The mounting shortage of healthcare personnel is imminent. The pandemic has further led to loss of workforce, causing a bleak outlook for hospital output around the globe, and leading to reduced access and continuity of care. That's why revolutionary automation like our blood drawing device is inevitable to solve the industry's biggest problem." Outpatient phlebotomy care is redefined At first, Vitestro will implement the device in outpatient phlebotomy departments. Patients will have the option to choose between Vitestro's venipunture device or standard method. The device is intuitive to use, empowering patients to be self-reliant in the full blood collection procedure. In previous clinical trials, patients of all ages showed a high degree of openness, enthusiasm and willingness to adopt the innovation. A trained healthcare professional is able to supervise several devices, managing multiple patients simultaneously. The increased efficiency enables hospitals and clinical laboratories to address workforce shortage or even free up staff and deploy them where they are really needed. "We have spent nearly five years on the development of this breakthrough medical device. All relevant disciplines are represented in our dedicated, specialized team of 35 people. To prepare for production and commercialization, the team will double in size in the next two years. We have clear momentum in the market and will be the first to bring autonomous technology to European hospitals. With our technology we can help to build a more robust and resilient healthcare system." Toon Overbeeke, Vitestro's Co-Founder and Chief Executive Officer Anja Leyte, Director OVLG Laboratories, participating in clinical studies commented: "By introducing automated blood drawing, high quality as well as capacity is guaranteed in our laboratories. Vitestro's technology helps solving staffing shortages at our blood drawing department and improving sample standardization. Patients are also very enthusiastic." About Vitestro In 2017 Vitestro's founders rose to the challenge to create a better blood drawing experience. Today Vitestro is well underway to achieve its goal with a committed team of 35 highly skilled people with a track record in medical robotics, imaging software, AI, QA/RA and business development. Vitestro is based in Utrecht, the Netherlands. Vitestro is well funded by private investors and government subsidies.

Read More

MEDICAL DEVICES

GeneQuantum Healthcare's Two Next Generation Bioconjugate Drugs, GQ1005 and GQ1007, Have Been Approved for Clinical Trials in Australia

GeneQuantum Healthcare | May 16, 2022

GeneQuantum Healthcare Co., Ltd. a global innovative biotechnology company dedicated to the development of bioconjugate drugs, announced that two of the company's bioconjugate drug candidates have won the approval for clinical trials in Australia, further enhancing GeneQuantum's pipelines in the clinical stage. They are GQ1005, an ADC with an excellent bystander killing effect, and GQ1007, a first-in-class antibody-immune-agonist-conjugateboth with global intellectual property rights. "The core technologies that we have focused on since the founding of GeneQuantum, bring the company into the harvest period for exciting next generation bioconjugate drugs. The EC approval of GQ1005 and GQ1007 in Australia is an important milestone for the company. More than once, GeneQuantum's enzymatic site-specific conjugation platform and the stable linker technology have demonstrated the advantages through several IND enabled drug candidates. GeneQuantum conjugation technologies are widely compatible to different molecular modalities with various Mechanism of Action. Committed to the core value of "breakthrough for humanity", GeneQuantum is dedicated to developing safe, effective, and affordable novel therapeutics for patients with cancer around the world." Dr. Gang Qin, founder, Chairman and Chief Executive Officer About GeneQuantum Healthcare Co., Ltd. GeneQuantum Healthcare Co., Ltd. is a global biotechnology company dedicated to the development of innovative biotherapeutics. The company is focused on the development of next generation bioconjugate therapeutics to address the unmet medical needs of patients globally. This press release contains statements relating to GeneQuantum's future business, future events or developments, and related statements may constitute forward-looking statements. Statements are based on current expectations and assumptions that are subject to risks and uncertainties, which may cause actual results to differ materially. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, follow-up clinical data and analysis; factors that may cause any delay, transfer or change; regulatory authority decision whether and when to approve drug applications; factors that may lead actual results to seriously deviate from current expectations, etc. No forward-looking statement can be guaranteed. Except as required by applicable laws, GeneQuantum assumes no obligation to update or revise any forward-looking information or statements.

Read More

Spotlight

Human resources executives are making significant investments in health benefits and health-related services for employees, but the Accolade Consumer Healthcare Experience Index survey indicates that they could get more for their healthcare investments by factoring how age and life circumstances influence how people use and experience their health benefits. These and other findings were drawn from a national survey conducted online by Harris Poll, on behalf of Accolade, an on-demand healthcare concierge for employers, health plans, and health systems.

Resources